@article{61eadbdaa515421687a67a02b8fe99ca,
title = "Natural cubic splines for the analysis of Alzheimer's clinical trials",
abstract = "Mixed model repeated measures (MMRM) is the most common analysis approach used in clinical trials for Alzheimer's disease and other progressive diseases measured with continuous outcomes over time. The model treats time as a categorical variable, which allows an unconstrained estimate of the mean for each study visit in each randomized group. Categorizing time in this way can be problematic when assessments occur off-schedule, as including off-schedule visits can induce bias, and excluding them ignores valuable information and violates the intention to treat principle. This problem has been exacerbated by clinical trial visits which have been delayed due to the COVID19 pandemic. As an alternative to MMRM, we propose a constrained longitudinal data analysis with natural cubic splines that treats time as continuous and uses test version effects to model the mean over time. Compared to categorical-time models like MMRM and models that assume a proportional treatment effect, the spline model is shown to be more parsimonious and precise in real clinical trial datasets, and has better power and Type I error in a variety of simulation scenarios.",
keywords = "DPM, MMRM, cLDA, constrained longitudinal data analysis, disease progression models, mixed model repeated measures, natural cubic splines",
author = "{for the Alzheimer's Disease Neuroimaging Initiative} and Donohue, {Michael C.} and Oliver Langford and Insel, {Philip S.} and {van Dyck}, {Christopher H.} and Petersen, {Ronald C.} and Suzanne Craft and Gopalan Sethuraman and Rema Raman and Aisen, {Paul S.}",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The FYN study (ClinicalTrials.gov identifier: NCT02167256) was supported by grant UH3 TR000967 (Drs Strittmatter, van Dyck, and Nygaard) from the National Center for Advancing Translational Sciences and grants P50 AG047270 (Dr. Strittmatter), P30 AG19610 (Dr. Reiman), and R01 AG031581 (Dr. Reiman) from the National Institute on Aging. See van Dyck, et al. 2019 for the complete FYN study team list and other acknowledgments. The Study of Nasal Insulin in the Fight Against Forgetfulness (ClinicalTrials.gov identifier: NCT01767909) led by Dr. Suzanne Craft was supported by NIH grant RF1 AG041845. The Mild Cognitive Impairment Study (ClinicalTrials.gov Identifier: NCT00000173) was led by Dr. Ronald C. Petersen and supported by NIH grants U19 AG010483 and UO1 AG10483. Funding Information: National Institute on Aging, Grant/Award Numbers: P30 AG19610, P50 AG047270, R01 AG031581, RF1 AG041845, U19 AG010483, U24 AG057437, UO1 AG10483; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health, Grant/Award Number: U01 AG024904 Funding information Funding Information: Dr. Donohue has consulted for Roche, received research funding from Eli Lilly and Eisai, and his spouse is a full‐time employee of Janssen. Mr. Langford has received research funding from Eli Lilly and Eisai. Dr. Insel has consulted for Roche and Merck. Dr. van Dyck serves as a scientific advisor for Eisai, Roche, Ono, and Cerevel and receives grant support for clinical trials from Biogen, Biohaven, Cerevel, Eisai, Eli Lilly, Genentech, Janssen, Roche, and UCB. Dr. Petersen has consulted for Roche, Merck, Genentech, Biogen, Nestle, Eisai and Lilly, and served on a DSMB for Genentech. Dr. Craft has received research support from Eli Lilly and serves on an SAB for T3D Therapeutics. Dr. Raman has received research funding from the National Institutes of Health, Alzheimer's Association, Eli Lilly and Eisai, and is the Board Chair (unpaid) of the Alzheimer's Association San Diego/Imperial Chapter. Dr. Aisen has research support from Eisai, Lilly and Janssen, and consults with Merck, Roche, Genetech, Abbvie, Biogen and ImmunoBrain Checkpoint. Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The FYN study ( ClinicalTrials.gov identifier: NCT02167256) was supported by grant UH3 TR000967 (Drs Strittmatter, van Dyck, and Nygaard) from the National Center for Advancing Translational Sciences and grants P50 AG047270 (Dr. Strittmatter), P30 AG19610 (Dr. Reiman), and R01 AG031581 (Dr. Reiman) from the National Institute on Aging. See van Dyck, et al. 2019 for the complete FYN study team list and other acknowledgments. The Study of Nasal Insulin in the Fight Against Forgetfulness ( ClinicalTrials.gov identifier: NCT01767909) led by Dr. Suzanne Craft was supported by NIH grant RF1 AG041845. The Mild Cognitive Impairment Study ( ClinicalTrials.gov Identifier: NCT00000173) was led by Dr. Ronald C. Petersen and supported by NIH grants U19 AG010483 and UO1 AG10483. Publisher Copyright: {\textcopyright} 2023 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.",
year = "2023",
month = may,
day = "1",
doi = "10.1002/pst.2285",
language = "English (US)",
volume = "22",
pages = "508--519",
journal = "Pharmaceutical Statistics",
issn = "1539-1604",
publisher = "John Wiley and Sons Ltd",
number = "3",
}